Related Experiment Video
Updated: May 31, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Treat ankylosing spondylitis with methazolamide
Xiaotian Chang1, Xinfeng Yan, Yunzhong Zhang
1National Laboratory for Bio-Drugs of Ministry of Health, Provincial Laboratory for Modern Medicine and Technology of Shandong, Research Center for Medicinal Biotechnology of Shandong Academy of Medical Sciences, Jingshi Road 18877, Jinan, Shandong 250062, P. R. China. changxt@126.com
International Journal of Medical Sciences
|July 14, 2011
Summary
Methazolamide, a carbonic anhydrase inhibitor, showed effectiveness in treating active ankylosing spondylitis (AS). This drug may help manage AS symptoms by targeting bone resorption and formation processes.
Area of Science:
- Rheumatology
- Pharmacology
- Biochemistry
Background:
- Ankylosing spondylitis (AS) is characterized by increased bone resorption and formation.
- Carbonic anhydrase inhibitors are known to reduce bone resorption.
- Elevated carbonic anhydrase I (CA1) expression was observed in AS synovium.
Purpose of the Study:
- To evaluate the efficacy and safety of methazolamide for treating active ankylosing spondylitis.
- To investigate the potential of targeting carbonic anhydrase activity in AS management.
Main Methods:
- Two patients with active AS were treated with methazolamide (25 mg twice daily).
- Disease activity was assessed using BASDAI and BASFI scores, ESR, and calcium levels.
- Radiographic changes in sacroiliac joints were evaluated using CT scans.
Main Results:
- Methazolamide treatment led to reduced BASDAI scores in both patients.
- Patient S showed improvement in BASFI and a decrease in ESR and calcium levels.
- CT scans indicated clearer articular surfaces and reduced calcification in sacroiliac joints, with no significant side effects.
Conclusions:
- Methazolamide demonstrated effectiveness in managing active ankylosing spondylitis.
- The drug may improve AS symptoms by inhibiting carbonic anhydrase activity involved in bone remodeling.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...